REG - Medpal AI PLC - Pharmacy Operational Update

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260407:nRSG3891Za&default-theme=true

RNS Number : 3891Z  Medpal AI PLC  07 April 2026

7 April 2026

 

MedPal AI plc

("MedPal AI" or the "Company")

 

Pharmacy Operational Update

 

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health
company, is pleased to announce a record month of pharmacy dispensing activity
at its wholly owned subsidiary, MedPal Limited.

 

Highlights:

·          Record month: 41,600 prescription items dispensed in
March 2026, the highest monthly volume since operations commenced,
representing growth of 27.5% month-on-month

·          Zero to scale in five months: Dispensing volumes have
grown from zero in October 2025 to over 41,600 items in March 2026,
demonstrating rapid scaling of the Company's automated pharmacy platform

·          Cumulative milestone: Total items dispensed since launch
has now reached approximately 200,000, underscoring sustained adoption of the
Company's NHS and private pharmacy services

·          Annualised revenue: Pharmacy operations now exceed £5
million in annualised turnover based on March 2026 dispensing volumes

·          Strong margins: Gross margin for March 2026 exceeded 34%,
reflecting the operational leverage of the Company's automated dispensing
infrastructure as volumes scale

 

The continued acceleration in dispensing volume demonstrates the increase in
patient demand across both NHS Distance Selling Pharmacy services and private
prescriptions through MedPal.clinic. The Company's technology-led cost
structure continues to support strong gross margins, which in March 2026
exceeded 34%. The Directors believe that the platform has substantial capacity
for further volume growth, which will deliver meaningful operating leverage as
fixed costs are absorbed over a larger revenue base.

 

Outlook

The Board remains highly confident in the Company's growth trajectory and the
significant market opportunity ahead. Key drivers of continued pharmacy growth
include:

·          Expanding NHS volumes: Growing patient adoption of the
Company's Distance Selling Pharmacy services, supported by 24/7 automated
robotic dispensing and rapid nationwide delivery

·          MedPal.clinic momentum: Continued strong demand for GLP-1
weight-loss treatments, with MedPal.clinic's AI-powered triage and zero-cost
consultation model providing a significant competitive advantage in a rapidly
expanding UK obesity market

·          Operational capacity: Substantial headroom within the
Company's robotic dispensing infrastructure to accommodate significantly
higher volumes without proportionate cost increases, providing a clear pathway
to improved profitability

 

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

 

"Dispatching over 41,000 items in March, our highest ever monthly total, is a
landmark moment. In just five months, we have scaled from zero to an
annualised pharmacy revenue run rate exceeding £5 million, and we have done
this while delivering a gross margin of over 34% in March. This extraordinary
rate of growth demonstrates the power of our vertically integrated, AI-driven
model.

 

"Our technology-led cost structure means that as dispensing volumes grow,
fixed costs are spread over a larger revenue base, driving further margin
improvement. The traditional pharmacy model is being disrupted, and MedPal is
leading that disruption. We look forward to updating the market on continued
progress."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer         Via Square1 Consulting

 Cairn Financial Advisers LLP                    +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited                   +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                              +44 (0) 20 7929 5599

 David Bick                                      +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS -
a vertically integrated, closed-loop platform spanning AI wellness, clinical
services, and automated pharmacy fulfilment. Its core app aggregates data from
over 100 wearable devices and health apps (including Apple Health, Fitbit,
Garmin, and Whoop) into a unified health profile, offering personalised,
non-clinical lifestyle guidance through its AI wellness coach and acting as
the consumer front door to the Company's clinical and pharmacy services.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages BD Rowa VMAX
robotic dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms. The Company's LEI is
984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUNRWRNSUSRAR



            Copyright 2019 Regulatory News Service, all rights reserved